The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the ...

Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo ...

Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is ...

Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic ...

Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedi ...

UK MHRA grants marketing approval to Galderma’s nemolizumab to treat prurigo nodularis and atopic dermatitis: United Kingdom Tuesday, February 18, 2025, 14:00 Hrs [IST] The Medi ...

These are the first approvals of nemolizumab from countries within the Access Consortium framework, with regulatory review processes ongoing in the ...

The CHMP has recommended nemolizumab’s approval for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged ZUG, Switzerland, November 28, 2024--Galderma (SWX ...

Sensorion (FR0012596468 ? ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today ...

CJRB-201', a proprietary strain of Faecalibacterium with potent its anti-inflammatory effects, has demonstrated the strongest induction of regulatory T cells (Tregs) among analyzed strains.Preclinical ...

Galderma's efforts to expand the market for Nemluvio are bearing more fruit. In Europe, officials approved the subcutaneous drug for the treatment of moderate-to-severe atopic dermatitis in ...